文献速递免疫规划传染病防控与疫情报告

鸭甲型肝炎病毒1型减毒疫苗E23-SP80的研制及其对鸭感染的保护效力评价

Development of duck hepatitis A virus type 1 attenuated vaccine E23-SP80 and its protective efficacy evaluation against DHAV-1 infection in ducks.
PubMed 文献 · Vaccine · 2026-01-23

本研究通过SPF鸡胚连续传代田间分离株,研制出鸭甲型肝炎病毒1型减毒疫苗候选株E23-SP80,病毒滴度为10^7.25 ELD50/0.2 mL,对2日龄樱桃谷鸭失去致病性且五轮回传未返强。单次肌注10^3.0 ELD50即可对致死性亲本株攻击提供100%保护,中和抗体滴度在接种后7至28天超过9 log2,显著高于商业疫苗。

要点

  • E23-SP80在SPF鸡胚中滴度达10^7.25 ELD50/0.2 mL,对2日龄鸭无致病性。
  • 单次肌注10^3.0 ELD50即可对致死性DHAV-1攻击提供100%保护。
  • 接种后7至28天中和抗体滴度超过9 log2,显著高于商业疫苗。

核心结论

  • E23-SP80株是防控DHAV-1感染的有前景的商业疫苗候选株。

研究设计与样本

  • 将DHAV-1田间分离株在SPF鸡胚中连续传代,获得减毒候选株E23-SP80。
  • 在2日龄樱桃谷鸭中评估致病性、五轮回传返强风险、免疫原性及攻毒保护效力。
  • 进行基因组分析比较E23-SP9与E23-SP80的氨基酸替换。

主要发现

  • E23-SP80在SPF鸡胚中适应生长,病毒滴度为10^7.25 ELD50/0.2 mL。
  • E23-SP80对2日龄樱桃谷鸭失去致病性,五轮回传后未返强。
  • 10^3.0 ELD50免疫剂量对致死性亲本DHAV-1株攻击提供100%保护。
  • 单次肌注后7至28天中和抗体滴度超过9 log2,显著高于商业疫苗。

关键数值与推荐

  • E23-SP80病毒滴度为10^7.25 ELD50/0.2 mL。
  • 免疫剂量10^3.0 ELD50提供100%攻毒保护。
  • 接种后7至28天中和抗体滴度超过9 log2。

临床怎么用

  • E23-SP80可作为DHAV-1减毒活疫苗候选株,单次肌注低剂量即可诱导高滴度中和抗体并提供完全保护。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Duck Hepatitis A Virus type 1 (DHAV-1) is a highly pathogenic virus that causes severe mortality in ducklings and results in substantial economic losses to the global duck industry. Live-attenuated DHAV vaccine remains one of the most effective strategies for controlling this disease. We developed a safe and effective live attenuated vaccine candidate E23-SP80 adapted to specific-pathogen-free (SPF) chicken embryos by serial passage of a field isolate. The E23-SP80 exhibited an adaptive growth capacity in SPF chicken embryos with a viral titer of 107.25 ELD50/0.2 mL and lost its pathogenicity in 2-day-old Cherry Valley ducklings. The vaccine strain maintained its attenuation and showed no virulence reversion after back propagation into 2-day-old ducklings for five rounds. An immunizing dose of only 103.0 ELD₅₀ of E23-SP80 could provide 100% protection against challenge with lethal parental DHAV-1 strain. After a single intramuscular vaccination, virus-neutralizing antibody titers exceeded 9 log2 from 7 to 28 days post-vaccination and the titers were markedly higher than those of a commercial vaccine. Genomic analysis of E23-SP9 and E23-SP80 revealed fifteen amino acid substitutions, most of which were located in VP1 and 2A2 proteins, and the hypervariable region of VP1 (T180I and D193N) might contribute to attenuation. These results suggest that E23-SP80 strain is a promising commercial vaccine candidate for the prevention and control of DHAV-1 infection.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Li J, Kyaw PE, Tan C, et al. Development of duck hepatitis A virus type 1 attenuated vaccine E23-SP80 and its protective efficacy evaluation against DHAV-1 infection in ducks. Vaccine. 2026. PMID: 41576706. doi:10.1016/j.vaccine.2026.128258

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。